In a report released on August 8, Colleen M. Kusy from Robert W. Baird reiterated a Buy rating on Agenus (AGEN – Research Report), with a price target of $8.00. The company’s shares opened today at $1.31.
M. Kusy covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, EyePoint Pharmaceuticals, and Iovance Biotherapeutics. According to TipRanks, M. Kusy has an average return of -22.4% and a 25.99% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Agenus with a $7.66 average price target, representing a 484.73% upside. In a report released on August 9, B.Riley Financial also reiterated a Buy rating on the stock with a $8.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $3.31 and a one-year low of $1.18. Currently, Agenus has an average volume of 5.04M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
Read More on AGEN:
- Agenus reports Q2 EPS (20c), consensus (20c)
- AGEN Earnings this Week: How Will it Perform?
- Jasper Therapeutics appoints Carlos as SVP, Marcantonio as VP
- Agenus names Robin Taylor, Homa Yeganegi, Stephanie Fagan to executive team
- Agenus reports data from Phase 1b trial of botensilimab/balstilimab combination
